Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, 13125, Berlin, Germany.
LIPIDOMIX GmbH, Robert-Rössle-Str. 10, 13125, Berlin, Germany.
Lipids Health Dis. 2023 Aug 29;22(1):138. doi: 10.1186/s12944-023-01906-z.
Oxylipins, the oxidative metabolites of polyunsaturated fatty acids (PUFAs), serve as key mediators of oxidative stress, inflammatory responses, and vasoactive reactions in vivo. Our previous work has established that hemodialysis affects both long chain fatty acids (LCFAs) and oxylipins in plasma and erythrocytes to varying degrees, which may be responsible for excess cardiovascular complications in end-stage renal disease. In this study, we aimed to determine changes in blood oxylipins during cardiopulmonary bypass (CPB) in patients undergoing cardiac surgery to identify novel biomarkers and potential metabolites of CPB-related complications. We tested the hypothesis that CPB would differentially affect plasma oxylipins and erythrocytes oxylipins.
We conducted a prospective observational study of 12 patients undergoing elective cardiac surgery with expected CPB procedure. We collected venous and arterial blood samples before CPB, 15 and 45 min after the start of CPB, and 60 min after the end of CPB, respectively. Oxylipins profiling in plasma and erythrocytes was achieved using targeted HPLC-MS mass spectrometry.
Our results revealed that most venous plasma diols and hydroxy- oxylipins decreased after CPB initiation, with a continuous decline until the termination of CPB. Nevertheless, no statistically significant alterations were detected in erythrocytes oxylipins at all time points.
CPB decreases numerous diols and hydroxy oxylipins in blood plasma, whereas no changes in erythrocytes oxylipins are observed during this procedure in patients undergoing cardiac surgery. As lipid mediators primarily responsive to CPB, plasma diols and hydroxy oxylipins may serve as potential key biomarkers for CPB-related complications.
氧化脂质是多不饱和脂肪酸（PUFAs）的氧化代谢产物，作为体内氧化应激、炎症反应和血管活性反应的关键介质。我们之前的工作已经确定，血液透析会在不同程度上影响血浆和红细胞中的长链脂肪酸（LCFAs）和氧化脂质，这可能是终末期肾病患者心血管并发症过多的原因。在这项研究中，我们旨在确定在接受心脏手术的患者中体外循环（CPB）期间血液氧化脂质的变化，以确定与 CPB 相关并发症相关的新的生物标志物和潜在代谢物。我们假设 CPB 会以不同的方式影响血浆氧化脂质和红细胞氧化脂质。
我们对 12 例行择期心脏手术且预计行 CPB 手术的患者进行了前瞻性观察性研究。我们分别在 CPB 前、CPB 开始后 15 和 45 分钟以及 CPB 结束后 60 分钟采集静脉和动脉血样。使用靶向 HPLC-MS 质谱法对血浆和红细胞中的氧化脂质进行了分析。
我们的结果表明，大多数静脉血浆二醇和羟基氧化脂质在 CPB 启动后下降，在 CPB 结束前持续下降。然而，在所有时间点，红细胞氧化脂质均未发生统计学上的显著变化。
CPB 会降低血液血浆中的许多二醇和羟基氧化脂质，而在心脏手术患者中，CPB 过程中红细胞氧化脂质没有变化。作为对 CPB 主要有反应的脂质介质，血浆二醇和羟基氧化脂质可能是 CPB 相关并发症的潜在关键生物标志物。
